Navigation Links
Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
Date:3/31/2009

el to areas where the virus circulates.

About IXIARO

Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization against the Japanese Encephalitis virus. The total development time of this vaccine took more than 10 years. The vaccine was developed under a Collaborative Research and Development Agreement with the Walter Reed Army Institute of Research, a biomedical research laboratory for the U.S. Department of Defense.

Intercell's Phase III trials for the vaccine found that the vaccine demonstrated excellent immunogenicity against Japanese Encephalitis and an overall clinical safety profile similar to placebo, combined with an excellent local tolerability profile. These data were published in The Lancet in December 2007:

  • The immunogenicity was comparable to that of the U.S. licensed product, JE-VAX(R).
  • Intercell's vaccine demonstrated an overall clinical safety profile similar to placebo.
  • Further, Intercell's Japanese Encephalitis vaccine had a more favorable local tolerability profile in the head-to-head study with JE-VAX(R).

About Intercell AG

Intercell AG is an innovative biotechnology company that designs and develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the company's first product on the market.

The Company's technology platforms include an antigen-discovery system, two proprietary adjuvants and a novel patch-based delivery system. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin and the Statens Serum Institut.

'/>"/>
SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
2. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
3. Iomai Stockholders Approve Merger With Intercell Subsidiary
4. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
5. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
6. New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
11. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 /PRNewswire/ ... research report is available in its catalogue: ... 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials are materials that are readily decomposed ... differs from conventional non-degradable packaging in terms ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... The Graphene Opportunity - A Rational ... Is Graphene The New Nanotech? A similar ... predictions of applications ranging from microelectronics to water ... today announced the availability of the Graphene Opportunity ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... Wis. - Lucigen Corp . and ... giving Lucigen exclusive worldwide rights to manufacture and sell ... , ,Under the agreement, Imaxio will retain the right ... applications, but Lucigen will provide the cells to commercial ...
... - It has yet to turn a profit, and it ... scope, but the decision by Madison research tool manufacturer NimbleGen ... to $75 million is the latest bit of evidence that the ... continues a pattern of growth and visibility for NimbleGen, which ...
... Alfalight , a manufacturer of high-power diode lasers, has ... million from the U.S. Army Research Laboratory . ... suitable for pumping high-power, fiber-laser systems, developed in conjunction ... commercial products. , ,Manoj Kanskar, vice president of research ...
Cached Biology Technology:Lucigen Corp. enters global licensing agreement 2IPO-bound NimbleGen traveling in fast company 2IPO-bound NimbleGen traveling in fast company 3IPO-bound NimbleGen traveling in fast company 4
(Date:8/28/2014)... kilometres of new roads will be built worldwide by ... last wildernesses, where they bring an influx of destructive ... ambitious study has created a ,global roadmap, for prioritising ... the competing demands of development and environmental protection. , ... estimates that natural importance of ecosystems and a ,road-benefits, ...
(Date:8/28/2014)... alert the world to Global Warming, has called for ... underground. He says that Carbon Capture, combined with limits ... avoid global warming getting out of control over the ... made the call during his presentation to the International ... meeting to discuss Carbon Capture and Storage. , ...
(Date:8/28/2014)... Biologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned ... genus of predatory arthropods. These animals lived in ... than related forms found in Jurassic strata. ... their shallow marine habitat and were fossilized some ... other denizens of the Silurian seas although ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Paleontology: Oldest representative of a weird arthropod group 2
... lung cancer patients most likely to respond to the drug ... drug cetuximab (Erbitux), according to a new study published in ... National Cancer Institute. Both drugs target the same gene ... lung cancer (NSCLC) have mutant versions of the epidermal growth ...
... by manipulating energy regulation of cells, a collaborative study ... cells lacking a tumor-suppressing kinase called LKB1 can still ... This energy regulation is essential for keeping cells ... signal new advances for combating cancerous tumor growth, but ...
... Investigators report safety findings and statistically significant improvements ... 19th Annual Symposia on the Etiology, Pathogenesis and ... Phase I trial showed positive interim results in ... treatment, patients exhibited a statistically significant improvement in ...
Cached Biology News:Treatments have same target, different responses for lung cancer patients with genetic mutation 2Energy management in cells may hold key to cancer defense 2Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 2Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 3Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 4Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 5Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 6
ANTI S. GROUP AG:H...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
... This service is for when you need to ... increase their transformation efficiency. Our services for preparing ... your applications. MCLab's custom competent cell service offers: ... ) Fast turnaround Quality ...
Biology Products: